共 212 条
[1]
Cartron G(2007)Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 62 43-52
[2]
Blasco H(2005)Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d’etude des lymphomes de l’adulte J Clin Oncol 23 4117-4126
[3]
Paintaud G(2003)Rituximab (Rituxan/MabThera): the first decade (1993–2003) Expert Rev Anticancer Ther 3 767-779
[4]
Watier H(2006)Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121-3127
[5]
Le Guellec C(2006)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379-391
[6]
Feugier P(2012)Biosimilars: what clinicians should know Blood 120 5111-5117
[7]
Van Hoof A(2013)Rituximab and biosimilars–equivalence and reciprocity Biosimilars 3 19-25
[8]
Sebban C(2002)Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 457-462
[9]
Solal-Celigny P(2002)Biogenerics: the off-patent biotech products Trends Pharmacol Sci 23 119-121
[10]
Bouabdallah R(2015)Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis Clin Pharmacokinet 54 29-33